245 related articles for article (PubMed ID: 18842000)
1. The BARD1 C-terminal domain structure and interactions with polyadenylation factor CstF-50.
Edwards RA; Lee MS; Tsutakawa SE; Williams RS; Nazeer I; Kleiman FE; Tainer JA; Glover JN
Biochemistry; 2008 Nov; 47(44):11446-56. PubMed ID: 18842000
[TBL] [Abstract][Full Text] [Related]
2. mRNA Processing Factor CstF-50 and Ubiquitin Escort Factor p97 Are BRCA1/BARD1 Cofactors Involved in Chromatin Remodeling during the DNA Damage Response.
Fonseca D; Baquero J; Murphy MR; Aruggoda G; Varriano S; Sapienza C; Mashadova O; Rahman S; Kleiman FE
Mol Cell Biol; 2018 Feb; 38(4):. PubMed ID: 29180510
[TBL] [Abstract][Full Text] [Related]
3. Structural basis to stabilize the domain motion of BARD1-ARD BRCT by CstF50.
Choudhary RK; Siddiqui MQ; Thapa PS; Gadewal N; Nachimuthu SK; Varma AK
Sci Rep; 2017 Jun; 7(1):3849. PubMed ID: 28634376
[TBL] [Abstract][Full Text] [Related]
4. Thermodynamic study of the BRCT domain of BARD1 and its interaction with the -pSER-X-X-Phe- motif-containing BRIP1 peptide.
Thanassoulas A; Nomikos M; Theodoridou M; Yannoukakos D; Mastellos D; Nounesis G
Biochim Biophys Acta; 2010 Sep; 1804(9):1908-16. PubMed ID: 20451671
[TBL] [Abstract][Full Text] [Related]
5. The BARD1 BRCT domain contributes to p53 binding, cytoplasmic and mitochondrial localization, and apoptotic function.
Tembe V; Martino-Echarri E; Marzec KA; Mok MT; Brodie KM; Mills K; Lei Y; DeFazio A; Rizos H; Kettle E; Boadle R; Henderson BR
Cell Signal; 2015 Sep; 27(9):1763-71. PubMed ID: 26022179
[TBL] [Abstract][Full Text] [Related]
6. Structural dynamics of clinically-reported VUS in the BARD1 ARD-BRCT region to predict the molecular basis of alterations.
Barua SA; Choudhary RK; Gawde J; Mishra N; Varma AK
J Biomol Struct Dyn; 2024 Jul; 42(11):5475-5484. PubMed ID: 37418175
[TBL] [Abstract][Full Text] [Related]
7. Crystal structure of the BARD1 BRCT domains.
Birrane G; Varma AK; Soni A; Ladias JA
Biochemistry; 2007 Jul; 46(26):7706-12. PubMed ID: 17550235
[TBL] [Abstract][Full Text] [Related]
8. Structural requirements for the BARD1 tumor suppressor in chromosomal stability and homology-directed DNA repair.
Laufer M; Nandula SV; Modi AP; Wang S; Jasin M; Murty VV; Ludwig T; Baer R
J Biol Chem; 2007 Nov; 282(47):34325-33. PubMed ID: 17848578
[TBL] [Abstract][Full Text] [Related]
9. A truncated splice variant of human BARD1 that lacks the RING finger and ankyrin repeats.
Tsuzuki M; Wu W; Nishikawa H; Hayami R; Oyake D; Yabuki Y; Fukuda M; Ohta T
Cancer Lett; 2006 Feb; 233(1):108-16. PubMed ID: 15878232
[TBL] [Abstract][Full Text] [Related]
10. Mechanisms of BRCA1-BARD1 nucleosome recognition and ubiquitylation.
Hu Q; Botuyan MV; Zhao D; Cui G; Mer E; Mer G
Nature; 2021 Aug; 596(7872):438-443. PubMed ID: 34321665
[TBL] [Abstract][Full Text] [Related]
11. Multimodal approach to explore the pathogenicity of BARD1, ARG 658 CYS, and ILE 738 VAL mutants.
Choudhary RK; Vikrant ; Siddiqui QM; Thapa PS; Raikundalia S; Gadewal N; Kumar NS; Hosur MV; Varma AK
J Biomol Struct Dyn; 2016 Jul; 34(7):1533-44. PubMed ID: 26307947
[TBL] [Abstract][Full Text] [Related]
12. Phosphopeptide binding specificities of BRCA1 COOH-terminal (BRCT) domains.
Rodriguez M; Yu X; Chen J; Songyang Z
J Biol Chem; 2003 Dec; 278(52):52914-8. PubMed ID: 14578343
[TBL] [Abstract][Full Text] [Related]
13. Thermal and chemical denaturation of the BRCT functional module of human 53BP1.
Thanassoulas A; Nomikos M; Theodoridou M; Stavros P; Mastellos D; Nounesis G
Int J Biol Macromol; 2011 Oct; 49(3):297-304. PubMed ID: 21600917
[TBL] [Abstract][Full Text] [Related]
14. Functional interaction of BRCA1-associated BARD1 with polyadenylation factor CstF-50.
Kleiman FE; Manley JL
Science; 1999 Sep; 285(5433):1576-9. PubMed ID: 10477523
[TBL] [Abstract][Full Text] [Related]
15. p53 inhibits mRNA 3' processing through its interaction with the CstF/BARD1 complex.
Nazeer FI; Devany E; Mohammed S; Fonseca D; Akukwe B; Taveras C; Kleiman FE
Oncogene; 2011 Jul; 30(27):3073-83. PubMed ID: 21383700
[TBL] [Abstract][Full Text] [Related]
16. Crystal structure of the BARD1 ankyrin repeat domain and its functional consequences.
Fox D; Le Trong I; Rajagopal P; Brzovic PS; Stenkamp RE; Klevit RE
J Biol Chem; 2008 Jul; 283(30):21179-86. PubMed ID: 18480049
[TBL] [Abstract][Full Text] [Related]
17. The BARD1-CstF-50 interaction links mRNA 3' end formation to DNA damage and tumor suppression.
Kleiman FE; Manley JL
Cell; 2001 Mar; 104(5):743-53. PubMed ID: 11257228
[TBL] [Abstract][Full Text] [Related]
18. The 3' processing factor CstF functions in the DNA repair response.
Mirkin N; Fonseca D; Mohammed S; Cevher MA; Manley JL; Kleiman FE
Nucleic Acids Res; 2008 Apr; 36(6):1792-804. PubMed ID: 18252771
[TBL] [Abstract][Full Text] [Related]
19. BRCA1 DNA-binding activity is stimulated by BARD1.
Simons AM; Horwitz AA; Starita LM; Griffin K; Williams RS; Glover JN; Parvin JD
Cancer Res; 2006 Feb; 66(4):2012-8. PubMed ID: 16489000
[TBL] [Abstract][Full Text] [Related]
20. Negative feedback loop of BRCA1-BARD1 ubiquitin ligase on estrogen receptor alpha stability and activity antagonized by cancer-associated isoform of BARD1.
Dizin E; Irminger-Finger I
Int J Biochem Cell Biol; 2010 May; 42(5):693-700. PubMed ID: 20060929
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
